India Anti-Fungal Drugs Market to grow with a CAGR of 10.49% through 2030
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the India Anti-Fungal Drugs Market
According
to TechSci Research report, “India Anti-Fungal Drugs Market Industry Size,
Share, Trends, Competition, Opportunity and Forecast, 2020-2030”, India Anti-Fungal Drugs Market
has valued at USD 1.06 Billion in 2024 and is anticipated to witness an
impressive growth in the forecast period with a CAGR of 10.49 % through
2030. This can be due to collaborations
and partnerships among leading companies with a diverse approach to merge the
expertise of individual companies and to strengthen their position in the
market.
Increased
awareness and improved diagnosis are key drivers of the demand for anti-fungal
drugs. Greater awareness among both healthcare professionals and the general
population about the signs and symptoms of fungal infections can lead to early
detection. Early diagnosis is crucial in effectively managing and treating
fungal infections. When fungal infections are identified promptly, healthcare
providers can initiate appropriate treatment, which often includes antifungal
drugs. This can help prevent the infection from progressing to a more severe or
invasive stage. Timely diagnosis and treatment of fungal infections can result
in better patient outcomes.
Fungal
infections, especially when left untreated or undiagnosed, can lead to serious
complications and, in some cases, life-threatening conditions. By raising
awareness and promoting early diagnosis, the demand for antifungal drugs
increases, as patients and healthcare providers seek effective treatments. In
some cases, antifungal drugs are used preventatively in patients who are at
high risk of fungal infections. This is common in immunocompromised
individuals, such as those undergoing cancer treatment or organ transplants.
Increased awareness of the risk factors for fungal infections may lead to more
proactive measures, including the use of antifungal medications as a preventive
strategy.
Browse
over XX market data Figures and spread through XX Pages and an in-depth TOC on
" India Anti-Fungal Drugs Market”
In October 2023, BDR Pharmaceuticals has introduced
Zisavel Capsules, a generic antifungal medication designed to address invasive
aspergillosis and mucormycosis. Zisavel, derived from isavuconazole, plays a
crucial role in the treatment of invasive aspergillosis. BDR Pharmaceuticals
aims to provide isavuconazole therapy at a cost comparable to voriconazole and
posaconazole, making it more accessible to financially disadvantaged patients.
Mucormycosis has a notably higher prevalence in India, with 140 cases per
million people, a rate that surpasses that of developed countries
significantly. In 2020, invasive aspergillosis resulted in approximately 2,360
fatalities.
Supply
chain and distribution issues pose challenges in the India Anti-Fungal Drugs
Market, affecting the availability and timely access to antifungal medications.
India has a highly fragmented distribution network with multiple intermediaries
involved in the supply chain. This complexity can lead to delays and
inefficiencies in the distribution of medications, including antifungal drugs.
There can be disparities in the availability of healthcare infrastructure and
pharmaceutical supply chains across different regions of India. Remote or
underserved areas may face greater challenges in obtaining essential
medications. Maintaining optimal inventory levels of antifungal drugs can be a
challenge for healthcare facilities and pharmacies. Stockouts or overstocking
can disrupt the availability of these drugs. In some cases, transportation
challenges, such as inadequate road infrastructure or logistical hurdles, can
impact the timely delivery of medications to healthcare facilities. Antifungal
drugs, like many medications, often require specific storage conditions to
maintain their efficacy. Ensuring that these conditions are met throughout the
supply chain can be challenging, especially in regions with variable climate
conditions.
India Anti-Fungal Drugs Market is segmented based
on drug class, indication, infection Type, Route of
Administration, End-user, Distribution Channel, and by region.
Based on the Indication, India Anti-Fungal Drugs
Market is segmented into Candidiasis, Aspergillosis, Dermatophytosis,
Mucormycosis, Others. Mucormycosis, often referred to as "black
fungus," is a severe and invasive fungal infection caused by a group of
molds known as mucormycetes. It is a significant concern within the context of
the Anti-Fungal Drugs market. Mucormycosis is
primarily caused by fungi from the order Mucorales, including Rhizopus, Mucor,
and Rhizomucor species. The
fungi that cause mucormycosis are ubiquitous in the environment and are
commonly found in soil and decaying organic matter. Infections typically occur
when fungal spores are inhaled or enter the body through wounds or mucous
membranes. Mucormycosis can manifest in various clinical forms, including
rhinocerebral (sinus and brain involvement), pulmonary (lung involvement),
gastrointestinal, cutaneous (skin and soft tissue), and disseminated (involving
multiple organs). Rhinocerebral mucormycosis is the most common form. Mucormycosis often requires aggressive
antifungal treatment, and not all antifungal drugs are equally effective
against these fungi. Amphotericin B, posaconazole, and isavuconazole are
commonly used antifungals for treating mucormycosis. The increased prevalence
of mucormycosis has led to greater demand for these specific antifungal drugs.
Based on Region, North India held the largest share in the India Anti-Fungal Drugs Market.
Pharmaceutical markets in India are influenced by various factors, including
the prevalence of diseases, healthcare infrastructure, patient demographics,
and the availability and affordability of medications. Fungal infections can
affect individuals across the country, and the market for antifungal drugs is
influenced by national healthcare trends and disease patterns.
Some
of the major companies operating in the India
Anti-Fungal Drugs Market include:
- Pfizer
India Ltd.
- Cipla
Ltd.
- Glenmark
Pharmaceuticals Ltd.
- Sun
Pharmaceuticals Industries Ltd.
- Dr.
Reddy's Laboratories Ltd.
- Viatris
Inc. (Mylan NV)
- Lupin
Ltd.
- Zydus
Cadila Ltd.
- Novartis
India Ltd.
- Abbott
Laboratories Ltd.
Download Free Sample Report
Customers can also request 10% free
customization on this report
“The India
Anti-Fungal Drugs Market is expected to witness steady growth in the coming
years, driven by rising incidences of fungal infections, particularly among
immunocompromised individuals, coupled with advancements in antifungal drug
development and increasing healthcare expenditure. Additionally, the growing
awareness about fungal infections and improved access to healthcare services
are anticipated to further bolster market expansion in India.," said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based Global management
consulting firm.
India
Anti-Fungal Drugs Market by Drug Class (Azoles, Echinocandins, Polyenes,
Allylamines, Others), By Indication (Candidiasis, Aspergillosis,
Dermatophytosis, Mucormycosis, Others), By Infection Type (Superficial Fungal
Infection, Systemic Fungal Infection), By Route of Administration (Parenteral,
Topical, Oral, Others), By End-User (Homecare, Hospitals, Clinics, Others), By
Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), By
Region, By Competition Forecast
& Opportunities, 2019-2029F has
evaluated the future growth potential of India Anti-Fungal Drugs Market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide innovative market intelligence and
help decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in India Anti-Fungal Drugs Market.
Contact Us-
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
M: +13322586602
Email: [email protected]
Website: www.techsciresearch.com